Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX Market Closed
Market Cap: 440.4B GBX

Relative Value

There is not enough data to reliably calculate the relative value of DPH.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DPH Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
578.3
Median 5Y
578.3
Industry
2.6
Forward
517.3
vs History
vs Industry
Median 3Y
-15 783.5
Median 5Y
5 046.2
Industry
21.6
Forward
2 980
vs History
vs Industry
Median 3Y
6 923.9
Median 5Y
6 531.1
Industry
16.5
vs History
vs Industry
Median 3Y
2 143.3
Median 5Y
2 143.3
Industry
22.5
vs History
vs Industry
Median 3Y
583.1
Median 5Y
583.1
Industry
2.3
vs History
vs Industry
Median 3Y
578.8
Median 5Y
578.8
Industry
2.9
Forward
517.8
vs History
vs Industry
Median 3Y
1 026
Median 5Y
1 026
Industry
5.5
vs History
vs Industry
Median 3Y
3 846.3
Median 5Y
3 846.3
Industry
13
Forward
1 926.1
vs History
vs Industry
Median 3Y
17 702.3
Median 5Y
6 691
Industry
16.6
Forward
2 795.1
vs History
vs Industry
Median 3Y
6 930.6
Median 5Y
6 533.3
Industry
15.8
vs History
vs Industry
Median 3Y
13 236.9
Median 5Y
11 688.6
Industry
19.1
vs History
vs Industry
Median 3Y
326.4
Median 5Y
326.4
Industry
1.9

Multiples Across Competitors

DPH Competitors Multiples
Dechra Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 16.4 52.8 35.5 38
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 5.5 20.3 16.6 21.5
CH
Roche Holding AG
SIX:ROG
252.3B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP 4.8 29.7 108 158
CH
Novartis AG
SIX:NOVN
202.4B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
249.5B USD 3.9 13.1 9.3 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
147B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
101.4B EUR 1.5 7.3 6.7 6.7
P/E Multiple
Earnings Growth PEG
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average P/E: 21.8
Negative Multiple: -15 783.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.8
53%
1
US
Johnson & Johnson
NYSE:JNJ
20.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
FR
Sanofi SA
PAR:SAN
7.3
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average EV/EBITDA: 399.4
3 846.3
36%
106.8
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
FR
Sanofi SA
PAR:SAN
6.7
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average EV/EBIT: 1 710.7
17 702.3
98%
180.6
US
Eli Lilly and Co
NYSE:LLY
38
36%
1.1
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3
FR
Sanofi SA
PAR:SAN
6.7
15%
0.4